Imagion Biosystems Ltd - Asset Resilience Ratio
Imagion Biosystems Ltd (IBX) has an Asset Resilience Ratio of 75.37% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IBX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2019)
This chart shows how Imagion Biosystems Ltd's Asset Resilience Ratio has changed over time. See what is Imagion Biosystems Ltd's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Imagion Biosystems Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Imagion Biosystems Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$4.33 Million | 75.37% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$4.33 Million | 75.37% |
Asset Resilience Insights
- Very High Liquidity: Imagion Biosystems Ltd maintains exceptional liquid asset reserves at 75.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Imagion Biosystems Ltd Industry Peers by Asset Resilience Ratio
Compare Imagion Biosystems Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 20.55% |
Annual Asset Resilience Ratio for Imagion Biosystems Ltd (2016–2019)
The table below shows the annual Asset Resilience Ratio data for Imagion Biosystems Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 69.82% | AU$3.40 Million ≈ $2.41 Million |
AU$4.87 Million ≈ $3.45 Million |
-14.37pp |
| 2018-12-31 | 84.19% | AU$4.37 Million ≈ $3.09 Million |
AU$5.19 Million ≈ $3.67 Million |
-5.76pp |
| 2017-12-31 | 89.94% | AU$6.87 Million ≈ $4.86 Million |
AU$7.64 Million ≈ $5.41 Million |
+89.72pp |
| 2016-12-31 | 0.23% | AU$27.64K ≈ $19.56K |
AU$12.14 Million ≈ $8.59 Million |
-- |
About Imagion Biosystems Ltd
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, … Read more